Scarica l'app Stockscreener
5.25
5.56%
0.03
Precedente Chiudi:
$5.22
Aprire:
$5.3
Volume 24 ore:
446
Relative Volume:
0.01
Capitalizzazione di mercato:
$173.27M
Reddito:
$7.80M
Utile/perdita netta:
$-69.02M
Rapporto P/E:
-2.6031
EPS:
-2.0168
Flusso di cassa netto:
$-66.61M
1 W Prestazione:
-2.04%
1M Prestazione:
-14.31%
6M Prestazione:
+39.14%
1 anno Prestazione:
+20.83%
Intervallo 1D:
$5.30
$5.30
Intervallo di 1 settimana:
$5.11
$6.17
Portata 52W:
$3.32
$12.70
Molecular Partners Ag Adr Stock (MOLN) Company Profile
Nome
Molecular Partners Ag Adr
Settore
Industria
Telefono
-
Indirizzo
-
Molecular Partners Ag Adr Stock (MOLN) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2022-08-30 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2022-08-29 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| 2022-05-25 | Aggiornamento | Credit Suisse | Underperform → Neutral |
| 2022-04-27 | Downgrade | Credit Suisse | Neutral → Underperform |
| 2021-07-13 | Iniziato | Cowen | Outperform |
| 2021-07-12 | Ripresa | SVB Leerink | Outperform |
Mostra tutto
Molecular Partners Ag Adr Borsa (MOLN) Ultime notizie
Why Sarepta Therapeutics Shares Are Trading Higher By Around 35%; Here Are 20 Stocks Moving Premarket - Benzinga
Wall Street Analysts See a 96% Upside in Molecular Partners AG Sponsored ADR (MOLN): Can the Stock Really Move ... - Yahoo News UK
Molecular Partners to Present at The TD Cowen Radiopharmaceutical Innovation Summit - GlobeNewswire Inc.
Molecular Partners' New Therapy Shows AML Treatment PromiseTipRanks.com - TipRanks
Molecular Partners Presents Positive Preclinical Data for First Switch-DARPin Candidate MP0621 at EHA 2024 - GlobeNewswire Inc.
Molecular Partners Unveils Promising Cancer Therapy - TipRanks
Molecular Partners and Orano Med Share Positive Preclinical Data of their DLL3-Targeting Radio-DARPin Therapy (RDT) Candidate MP0712 at SNMMI 2024 - GlobeNewswire Inc.
Why GameStop Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket By Benzinga - Investing.com UK
Molecular Partners Shares Rise on Positive Trial Data for MP0317 - MarketWatch
Molecular Partners Presents Positive Data From Completed Phase 1 Trial Of MP0317 (FAP X CD40 DARPin) Monotherapy In Patients With Advanced Solid Tumors At ASCO 2024 - GlobeNewswire Inc.
Interim Management Statement Q1 2024 of Molecular Partners: Pipeline Progressing with Two Additional Programs to Enter the Clinic in 2025, Update to MP0533 Program - GlobeNewswire Inc.
Novartis (NVS) & Molecular Partners Initiate Study for COVID-19 - Yahoo Singapore News
Molecular Partners Announces Publication in Cancer Immunology Research of Preclinical Data Supporting MP0533’s Proposed Mechanism of Action - GlobeNewswire Inc.
Life Science Cares Launches in Switzerland - GlobeNewswire Inc.
Molecular Partners Announces All Board Proposals Approved at the Annual General Meeting - GlobeNewswire Inc.
Molecular Partners Publishes Invitation to Annual General Meeting 2024 - GlobeNewswire Inc.
Rigel Pharmaceuticals names new Chief Medical Officer By Investing.com - Investing.com
Molecular Partners: Sellers Have Disappeared, Enterprise Value Below Zero (NASDAQ:MOLN) - Seeking Alpha
U.S. shares mixed at close of trade; Dow Jones Industrial Average up 0.19% - Investing.com UK
US stock market gainers for the last week of April 2022 - Nairametrics
U.S. shares mixed at close of trade; Dow Jones Industrial Average down 0.45% - Investing.com India
The Daily Biotech Pulse: Novartis COVID-19 Drug Readout, Merck And Roche Earnings, 3 IPOsiShares Biote - Benzinga
Molecular Partners (MLLCF) Stock Price, News & Analysis - MarketBeat
ADVFNFree stock and cryptocurrency prices, charts, market news and streaming real-time quotes. - ADVFN
Molecular Partners Ag Adr Azioni (MOLN) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.26%
1.63%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Capitalizzazione:
|
Volume (24 ore):